Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI (CORIMUNO-SARI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04324073

Recruitment Status : Unknown

Verified March 2020 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Active, not recruiting

First Posted : March 27, 2020

Last Update Posted : April 15, 2020

Sponsor:

Information provided by (Responsible Party):

Assistance Publique - Hôpitaux de Paris

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	March 27, 2021
Estimated Study Completion Date :	December 31, 2021

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Hermine O, Mariette X, Porcher R, Resche-Rigon M, Tharaux PL, Ravaud P; on the behalf of the CORIMUNO-19 collaborative group. Effect of Interleukin-6 Receptor Antagonists in Critically Ill Adult Patients with COVID-19 Pneumonia: two Randomised Controlled Trials of the CORIMUNO-19 Collaborative Group. Eur Respir J. 2022 Feb 3. pii: 2102523. doi: 10.1183/13993003.02523-2021. [Epub ahead of print]

CORIMUNO-19 Collaborative group. Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. Lancet Rheumatol. 2022 Jan;4(1):e24-e32. doi: 10.1016/S2665-9913(21)00315-5. Epub 2021 Nov 17.

To Top